New York City, New York Dec 18, 2023 – Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative precision biologics, today announced its selection as an awardee of the Science in the City QuickFire Challenge launched by Johnson & Johnson Innovation LLC. As part of the award, Manhattan Bio will receive a one-year residency at JLABS @ NYC, including laboratory space, access to equipment, and connection to the global Johnson & Johnson Innovation network of experts.
The QuickFire Challenges are designed to accelerate game-changing, early-stage innovations in the pharmaceutical and medical device sectors. With unique biologic platforms focusing on RNA degraders (RNADs) and antibody-drug conjugates (ADCs), Manhattan Bio is building a pipeline of medicines targeting selective vulnerabilities to treat cancers and other diseases. Manhattan Bio’s lead program, MABS-139, is a rationally designed RNA-degrading protein which exhibits broad anti-tumor efficacy in preclinical animal models and successfully completed Phase 1 dose-escalation study, yielding promising results. Additional programs being developed via internal R&D efforts and in collaboration with the National Cancer Institute and Binghamton University include ADCs utilizing proprietary tumor-cleavable linker-payload chemistries for targeted delivery of next-generation warheads to the tumor cells.
“We are very excited to be selected for QuickFire Challenge award,” said Dr. Borys Shor, CEO of Manhattan Bio. “The network and resources available to us will be valuable as we continue to build out a broad pipeline of protein- and antibody-based therapeutics and accelerate progress toward the clinic. We greatly appreciate this recognition of our talented team’s dedication to advancing breakthrough innovations for patients”
About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of biologic immunotherapies targeting host defense pathways for the treatment of advanced cancers. The company advances two technology platforms for drug discovery: RNA-degrader proteins, and antibody-drug conjugates (ADCs) – through collaborations with leading academic institutions. Manhattan Bio has established partnerships with the National Cancer Institute (NCI), Stony Brook University, The University at Buffalo, Binghamton University, INSERM, Nascent Biotech, EVQLV, Biocytogen and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT), the New York State Center For Biotechnology and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT). Learn more at manhattanbiosolutions.com and follow Manhattan BioSolutions on LinkedIn or Twitter.
Contact for investor inquiries:
Jordana Lovett, PhD
Director of Investor Relations
(857) 600-1021
